Seeking reliable custom monoclonal antibodies that target your most challenging antigens? Trust the antibody experts at ProteoGenix. With over 20 years of experience, 30+ antibodies in clinical and pre-clinical trials, and 3 therapeutic antibodies on the market, ProteoGenix knows how to build your next high-quality custom monoclonal antibody. From antibody discovery to production, including vital modifications, our monoclonal antibody services are adaptable, letting you fine-tune projects to your exact specifications. Whether it’s therapeutics, diagnostics, or research, we can build your custom antibody to exceed your most challenging research or clinical specifications. Let’s have a conversation about your custom monoclonal antibody needs today !

About us – Your custom monoclonal antibodies partner since 2003

Established in 2003, ProteoGenix’s journey began in diagnostic assays and biotherapeutics, fueling protein discovery. As protein identification thrived, our proficiency in producing high-performing antibodies grew. Recognized for our superior in-house custom monoclonal antibody production, we expanded our mission to become an antibody production company.

ProteoGenix has since transformed into a leader in producing custom monoclonal antibodies recognized globally as a full-service antibody company. From antigen design and production to antibody engineering, and antibody development, our monoclonal antibody services are comprehensive.

Have ProteoGenix Become An Extension of Your Team’s Capabilities

At ProteoGenix, we understand that starting a custom monoclonal antibody project requires trust, open communication, and a clear understanding of your unique needs and expectations. Your project’s success depends on collaboration between your team and our antibody experts. That is why building your trust is our number one priority. We do this using the following approaches.

  • Understanding Your Expectations

We begin by scheduling a free consultation with one of our antibody experts. Here we will gain insights into your project and recommend monoclonal antibody development strategies that align with your project goals. We will also ensure that we can meet your project’s timelines and budget constraints.

  • Transparency and Decision Points

We consider ourselves an extension of your team, and your priorities become our priorities. Throughout the project, we maintain open lines of communication, sharing progress and addressing any concerns promptly. We also implement go/no-go checkpoints. These are key milestones in the project that allow you to determine whether to progress further or not. This gives you complete control of the project’s direction and financial aspects.

  • Building Trust Together

Our commitment to transparency, personalized strategies, and continuous communication isn’t just about delivering results; it’s about building trust. We want you to feel confident that you’ve made the right choice by partnering with ProteoGenix.

  • Your Success Is Our Goal

Ultimately, the decision to proceed or terminate the project rests with you. Our mission is to empower you with the information and support needed to make informed choices. Your success is our ultimate goal, and we’re dedicated to helping you achieve it.

Six reasons why you should think about using monoclonal antibodies instead of polyclonal antibodies

In the world of antibody-based research and diagnostics, the choice between monoclonal and polyclonal antibodies can significantly impact the outcome of your experiments or applications. While both types have their merits, here are six compelling reasons why monoclonal antibodies offer more dynamic capabilities compared to polyclonal antibodies.

  • Reproducibility – Never worry about running out of your custom antibody again. Unlike polyclonal antibodies, monoclonal antibodies have no batch-to-batch variation because they are derived from DNA sequences.


  • Specificity – Monoclonal antibodies recognize a distinct epitope on an antigen. This minimizes background crossreactivity that can be observed with polyclonal antibodies.


  • No Antigen Limits – Some antigens such as toxins require an animal-free monoclonal antibody production strategy such as antibody phage display. Thus, unlike polyclonal antibodies, monoclonal antibodies can be produced against many diverse antigens regardless of toxicity.


  • No Species Limitations – Producing a custom monoclonal antibody using phage display means we can make your custom monoclonal antibody in whatever species you prefer. We offer a wide range of naive libraries including, mouse, sheep, llama, rabbit, and dog.


  • Antibody Engineering – Monoclonal antibodies are derived from a single, well-characterized clone, allowing for precise genetic engineering and consistent modification.


  • Scalability –Monoclonal antibodies are derived from a single clone making it easier to produce large batches of recombinant monoclonal antibodies at scale. Conversely, the production of polyclonal antibodies is constrained by the capacity of the immunized animal to generate them.

How much does it cost to develop Custom Monoclonal Antibodies?

Understanding the financial investment required for custom monoclonal antibody production is a crucial consideration. While specific costs can vary based on multiple factors, they generally begin around 5000€ and can extend to several tens of thousands of euros. The final expense is determined by factors such as the intended application, the strategy employed (whether it involves proteins, peptides, or constructing a sandwich ELISA), the number of antibody binders needed, and whether or not immune library construction is required.

At the heart of the pricing structure is the complexity of your project. For example, developing custom monoclonal antibodies for research projects is cheaper than for therapeutic development or clinical diagnostics assays. This is because the latter usually involves more intricate processes and project timelines, leading to a larger total investment.

It’s crucial to remember that while cost is a factor, the value gained from acquiring customized monoclonal antibodies tailored to your needs can far outweigh the financial consideration. The expertise, precision, and innovation involved in the development process contribute to the production of antibodies that can catalyze breakthroughs in research, diagnostics, and therapeutic applications.

Why choosing the correct first step can limit future investment?

Making informed choices from the beginning is paramount when producing your custom monoclonal antibody. Your initial strategy and decisions can significantly impact not only the immediate costs but also the long-term investment in engineering steps.

By selecting the right starting strategy, you can streamline the development process, potentially avoiding the need for multiple costly iterations and modifications down the road. This approach not only conserves your resources but also accelerates the timeline to obtaining the precise antibodies you require.

Why choosing the wrong first step can cost you?

The easiest way of explaining how poor antibody consultation advice can cost you is by providing a common example.
If you want to produce a therapeutic custom monoclonal antibody that targets a human cell surface glycoprotein, then selecting the hybridoma production method might seem like the most suitable option.

After all, it’s cheaper than the B cell screening and the antibody phage display methods and hybridoma cell lines are known for generating high-affinity monoclonal antibodies.

However, this route might be significantly more costly and time-consuming in the long run for the following reasons.


1. Antigen Limitations:  Obtaining high-affinity monoclonal antibodies to a glycosylated protein using the hybridoma antibody production method is difficult due to immune tolerance mechanisms, complex glycan structures, and potential epitope masking. This makes alternative methods like antibody phage display and B cell screening more suitable.


2. Affinity Maturation Steps Required:  Using the hybridoma method to make an antibody against a glycoprotein will likely result in the production of an antibody with limited specificity. To fix this issue you will need to alter the amino acid sequence of the monoclonal antibody to enhance its affinity to the glycoprotein, an additional service called affinity maturation. Other antibody production methods are more likely to avoid this pitfall such as B cell screening and antibody phage display.


3. Humanization Steps Required:  Next, using the hybridoma method to make a human therapeutic antibody will require an additional antibody humanization step that other techniques such as antibody phage display do not require.


4. Deliverables are Cell Lines:  The hybridoma antibody production method delivers a hybridoma cell line. Cell lines have disadvantages including genetic instability, contamination risks, and limited scalability, making them resource-intensive and less adaptable for large-scale therapeutic antibody production. In contrast, monoclonal antibody production methods such as B cell screening and antibody phage display deliver DNA sequences.

Our antibody experts can navigate these intricacies, helping clients choose the most suitable approach tailored to their specific needs. This can help you make informed decisions from the beginning that will significantly improve your odds of producing a superior custom antibody.


How long does it take to develop Custom Monoclonal Antibodies?

The timeline for custom monoclonal antibody production varies significantly based on a multitude of factors. From as short as 3 weeks for a phage display using a naive library to several months for hybridoma methods, the duration is subject to the technology employed, specific deliverables requested, and the complexity of the project.

The choice of technology is a pivotal factor influencing the development timeline. Techniques like phage display, especially with a naive library, can yield rapid results due to the streamlined nature of the process. In contrast, hybridoma approaches, which involve the fusion of immune cells, might necessitate more time.

Additionally, the final application of the antibodies plays a role in determining the timeframe. Customer testing, purification requirements, and other specific demands can extend the development period. Ultimately, the timeline’s flexibility caters to your project’s unique needs, ensuring that the final product meets your expectations and specifications.

RocketAbs Immunization Platform

Our proprietary RocketAbs immunization platform is designed to revolutionize the custom monoclonal antibody production processes, specifically for antibody production methods like B cell sorting and hybridoma techniques . RocketAbs is engineered to accelerate the immunization phase, significantly reducing the time required for custom monoclonal antibody production in mice and rats.

Compared to conventional methods, RocketAbs boasts up to a remarkable 50% reduction in the time needed for successful antibody generation in vivo. This breakthrough platform offers a substantial advantage, expediting research timelines and enabling quicker access to crucial antibodies.

Our dedication to cutting-edge technology underscores our commitment to efficiency and excellence. With RocketAbs, we’re not only delivering results faster but also enhancing the precision and quality of the generated antibodies.

Which monoclonal antibody generation service is the most adapted to my project?

Selecting the ideal monoclonal antibody production service hinges on your project’s unique requirements. Here’s a brief guide to help you make an informed choice:

    • Short Timeline: If time is of the essence, consider phage display on naive libraries. This method bypasses the need for an extended immunization protocol, enabling rapid antibody discovery and selection. However, if phage display is not an option for you, our RocketAbs immunization platform used for hybridoma and B cell sorting services reduces the time to delivery by up to 50%.


    • Limited Budget: If cost-effectiveness is a priority, hybridoma technology stands out as the best choice. This monoclonal antibody production service is known for its budget-friendly nature while delivering reliable, high affinity monoclonal antibodies.


    • Toxic Antigen: When dealing with a toxic antigen, traditional immunization might not be a viable option. In this scenario, phage display is the clear preferred approach, allowing antibody production without the need for exposing animals to toxic substances.

Choosing the right method ensures that your project’s constraints and objectives are met, facilitating efficient antibody production that aligns precisely with your goals.

Variable Antibody Phage Display Hybridoma Development B Cell Sorting
Time to Produce +++ + ++
Cost ++ +++ ++
Antibody Format scFv, VHH, Fab Full IgG Full IgG
Suitable for Toxic Antigens? Yes No No
Species Limitations None Rabbit, Rat, Mouse Rabbit
Antibody Affinity Moderate High High
Antibody Developability Moderate High High
Human antibody possibilities Not if a human library is used Yes Yes